Tian Zhang: Should not skip definitive treatments in prostate cancer
Tian Zhang shared on X:
“Lots of ongoing questions for PSMA PET from Dana Rathkopf— XRT to PSMA avid lesions vs primary?
We at UTSW Simmons Cancer Center have data suggesting time to castration resistance is long and this is early met disease — should not skip definitive treatments.”
Source: Tian Zhang/X
Dr. Tian Zhang, an Associate Director of Clinical Research at Simmons Comprehensive Cancer Center and an Associate Professor at UT Southwestern Medical Center, specializes in diagnosing and treating genitourinary cancers, including kidney, prostate, bladder, and testicular cancers.
She focuses on clinical trials and translational research to develop new therapies and evaluate biomarkers for these malignancies. Dr. Zhang is a member of ASCO, AACR, and ESMO.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023